Pricing Log in Create free account

Adaptimmune Therapeutics PLC (ADAPY) vs Lipocine Inc. (LPCN)

Adaptimmune Therapeutics PLC and Lipocine Inc. are both Biotechnology companies. Adaptimmune Therapeutics PLC and Lipocine Inc. are of similar size ($14.6M and $13.9M). Adaptimmune Therapeutics PLC grew revenue faster over the last twelve months: −54.0% against −63.5%. Adaptimmune Therapeutics PLC has the higher net margin (−262.5% vs −755.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Adaptimmune Therapeutics PLC leads on 9 and Lipocine Inc. on 7.

Valuation

Metric ADAPY LPCN Biotechnology median
P/E n/m n/m 8.50
P/S 0.12 7.75 9.71
P/B n/m 0.56 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.64 0.64
EV/Sales 0.12 (5.21) 9.21
Earnings yield (2,166.67%) (126.35%) (33.15%)
Free cash flow yield (2,380.45%) (92.84%) (25.50%)

Profitability

Metric ADAPY LPCN Biotechnology median
Gross margin 94.81% 100.00% 65.16%
Operating margin (427.75%) (800.80%) 0.00%
Net margin (262.46%) (755.11%) 0.00%
Free cash flow margin (288.20%) (713.02%) 0.00%
Return on equity (1,349.52%) (60.94%) (56.36%)
Return on assets 0.00% (55.89%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ADAPY LPCN Biotechnology median
Revenue growth (TTM) (53.99%) (63.48%) 6.02%
EPS growth (last fiscal year) 142.86% (93,988.89%) 30.26%
Revenue growth, 5-year CAGR 8.40% 64.32% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADAPY LPCN Biotechnology median
Debt to equity (0.36) 0.00 0.00
Current ratio 1.52 11.48 4.72
Net debt to EBITDA 0.47 1.42 0.96

Dividend

Metric ADAPY LPCN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ADAPY LPCN Biotechnology median
Market cap 14.55m 13.85m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack